AbCellera Biologics Inc. (ABCL) - Q3 2025 10-Q Summary
Business Context and Reporting Period
This report covers the quarterly period ended September 30, 2025. AbCellera Biologics Inc. is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in endocrinology, women's health, immunology, and oncology. The company operates a dual strategy of advancing internal programs and partnering with pharmaceutical companies to build a diversified portfolio of royalty stakes.
Key Financial Metrics
| Metric (in thousands, except per share) | Q3 2025 | Q3 2024 | 9M 2025 | 9M 2024 |
|---|---|---|---|---|
| Total Revenue | $8,955 | $6,507 | $30,275 | $23,783 |
| Net Loss | $(57,119) | $(51,107) | $(137,467) | $(128,647) |
| Net Loss Per Share (Basic/Diluted) | $(0.19) | $(0.17) | $(0.46) | $(0.44) |
| Cash, Cash Equivalents & Marketable Securities | $495,672 | $625,614 (Dec 31, 2024) | N/A | N/A |
| Operating Cash Flow (9M) | $(96,552) | $(100,556) | N/A | N/A |
| Total Assets | $1,355,992 | $1,360,553 (Dec 31, 2024) | N/A | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Total revenue increased 38% in Q3 2025 compared to Q3 2024, driven primarily by a 40% increase in research fees ($8.8M vs $6.3M). For the nine months ended September 30, 2025, revenue grew 27% to $30.3M, largely due to a significant increase in licensing revenue ($10.8M vs $0.8M in the prior year period), partially offset by the absence of milestone payments recognized in 2024.
- Expense Management: Total operating expenses decreased 15% in Q3 2025 ($85.2M) compared to Q3 2024 ($100.2M). This reduction was primarily driven by a decrease in depreciation, amortization, and impairment charges, which fell from $36.9M in Q3 2024 to $5.2M in Q3 2025. The 2024 period included significant impairment charges related to acquired in-process research and development (IPR&D) from Trianni and TetraGenetics.
- Research & Development (R&D): R&D expenses increased 34% in Q3 2025 ($55.0M) compared to Q3 2024 ($41.0M), reflecting increased headcount and specific investments of $15.0M in two internal programs.
- Liquidity: Total cash, cash equivalents, and marketable securities decreased by approximately $130M from year-end 2024 to $495.7M as of September 30, 2025, due to operating cash outflows and capital expenditures for the corporate headquarters and clinical manufacturing facility.
Guidance, Outlook, and Risks
- Clinical Progress: The company achieved a critical regulatory milestone in Q2 2025 with the submission of Clinical Trial Applications (CTAs) to Health Canada for ABCL635 (menopause vasomotor symptoms) and ABCL575 (atopic dermatitis). Dosing for Phase 1 trials for both programs commenced in the second half of 2025. A third program, ABCL688 (autoimmunity), advanced to IND/CTA-enabling studies with a submission anticipated in 2026.
- Capital Resources: Management believes current liquidity ($495.7M in cash/securities plus loan receivables and government contributions) is sufficient to meet working capital and capital expenditure needs for at least the next 36 months. No additional external funding is anticipated in this timeframe.
- Key Risks:
- Profitability: The company has incurred losses since inception and expects to continue incurring losses as it invests in R&D and infrastructure.
- Regulatory & Development: Success depends on the advancement of internal programs and the success of partners in developing and commercializing discovered antibodies. There is no guarantee of regulatory approval or commercial success.
- Intellectual Property Litigation: The company is engaged in patent infringement litigation against Bruker Cellular Analysis, with a jury trial scheduled for January 2026. An appeal regarding the validity of AbCellera's patents was confirmed by the CAFC in May 2025.
- Government Contributions: Significant portions of funding from the Government of Canada and British Columbia are conditionally repayable based on future revenue thresholds.
Investor Verification Checklist
- Verify the status and enrollment progress of Phase 1 clinical trials for ABCL635 and ABCL575.
- Monitor the outcome of the patent infringement litigation against Bruker Cellular Analysis scheduled for January 2026.
- Review the terms of government contribution agreements to understand the conditions triggering repayment of the $166.7M (Canada) and $55.6M (BC) commitments.
- Assess the timeline for the completion of the corporate headquarters and clinical manufacturing facility and the associated capital expenditure burn rate.
- Track the initiation of new partner programs and the recognition of licensing revenue versus research fees.